Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > News out!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(61)
•••
Comment by snootchybootchyon Apr 05, 2017 7:40am
109 Views
Post# 26077795

RE:RE:News out!

RE:RE:News out!
GoldenDilemma wrote:

AKA - Yosprala is a failure.

Sorta sounds like when CXRX cut their dividend of (which was only a few million in savings) to pay off their few billion or so in debt.


I do not see the connection with CXR.  And too early to say Yosprala is a failure.  Again, I've given examples on this board of new drugs that started slow after launch but began to exponentailly grow their sales after a couple of years.  Time will tell with Yosprala.  Aralez is planning to market Yosprala in combination with Zontivity and we have not seen the results of that combination.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities